The German Vaccine Board recommends that people under 60 receive the first dose of AstraZeneca’s COVID-19 vaccine and not the second dose.
Reuters report The committee, called STIKO, recommends that people receive a dose of mRNA-based vaccine 12 weeks after receiving the first dose of AstraZeneca, such as a vaccine from Pfizer/BioNTech or Moderna.
According to Reuters, STIKO said: “Pending appropriate data, STIKO recommends that people under 60 should be given a second dose of AstraZeneca 12 weeks after the first vaccination, instead of a second dose of AstraZeneca. ”
STIKO pointed out that according to the telecommunications service, there is no scientific evidence on the safety of the mixed vaccine series.
The suggestion comes from Germany not in service The AstraZeneca vaccine is aimed at people under the age of 60 because of concerns that blood clots are rare in the minority of people receiving the vaccine.
STIKO was planning to issue recommendations for those who received the first dose of the drug before the end of April.
A few countries have suspended or suspended the use of AstraZeneca’s COVID-19 vaccine because there have been reports of blood clots in a small number of patients.
The National Advisory Committee on Immunization of Canada recommended on Monday that the vaccine should not be used in adults under 55 because it investigates concerns about blood clotting.
European Medicines Agency Said Wednesday There may be a small amount of blood clots, but there is no evidence that the vaccine is associated with an increased risk of blood clots.
AstraZeneca Said in late March Its vaccine has an effective rate of 76% against symptomatic COVID-19, and it plans to apply for emergency use permission from the U.S. Food and Drug Administration.